We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+0.35%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$193M
AUM Growth
-$22.9M
Cap. Flow
-$75M
Cap. Flow %
-38.89%
Top 10 Hldgs %
99.96%
Holding
13
New
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 42.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SLXP
1
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$46.9M 24.29%
300,000
HRTX icon
2
Heron Therapeutics
HRTX
$86.3M
$41M 21.23%
4,919,625
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18.4M 9.52%
1,911,462
+1,029,555
+117% +$10.2M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.5B
$13.2M 6.82%
182,300
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.05M 2.62%
288,432
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.68M 1.91%
300,000
-700,000
-70% -$8.13M
PHIO icon
7
Phio Pharmaceuticals
PHIO
$12.1M
0
DNDN
8
DELISTED
DENDREON CORPORATION
DNDN
$80K 0.04%
55,548
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
-465,763
Closed -$3.07M
AMBI
10
DELISTED
Ambit Biosciences Corp
AMBI
$0 ﹤0.01%
46

Similar funds

Tang Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Tang Capital Management held 13 positions worth $193M, down 11% from $216M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tang Capital Management withdrew a net $75M in Q3 2014, closing 1 position and reducing 1 holding. Its most notable exit was Endocyte, Inc. Common Stock, an estimated $3.07M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 48% a quarter earlier.

Against the trend, Tang Capital Management added an estimated $10.2M to La Jolla Pharmaceutical Company.

  • Tang Capital Management added most to La Jolla Pharmaceutical Company in Q3 2014, an estimated $10.2M increase.
  • Tang Capital Management's biggest Q3 2014 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $8.13M.
  • Tang Capital Management fully exited Endocyte, Inc. Common Stock in Q3 2014, selling an estimated $3.07M.
  • Tang Capital Management's ten largest holdings make up 100% of its $193M portfolio in Q3 2014.
  • Tang Capital Management opened 0 new positions and closed 1 in Q3 2014.
  • Tang Capital Management's portfolio value fell 11% quarter-over-quarter to $193M.

Based on Tang Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.